Takashi Kei Kishimoto

This inventor holds 26 USPTO granted patents and 67 published patent applications, plus 8 CIPO patents and 13 EPO patents, primarily in Immunotherapy Nanocarriers. Top assignees: Selecta Biosciences, Inc., Momenta Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc.. Active years: 2003-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takashi Kei Kishimoto. Retrieved from https://idiyas.com/inventor/takashi-kei-kishimoto

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 67)

% Patents Active = 80.8

CIPO Patents = 8 (Patent Applications = 33)

EPO Patents = 13 (Patent Applications = 49)

Average Co-Inventor Count = 2.2

ph-index = 11

Forward Citations = 240(Granted Patents)

Company Filing History:

14 out of 32

Selecta Biosciences, Inc.

patents

9 out of 121

Momenta Pharmaceuticals, Inc.

patents

1 out of 278

Boehringer Ingelheim Pharmaceuticals, Inc.

patents

4. 1 out of 8

Cartesian Therapeutics, Inc.

patents

5. 1 out of 834,570

Other

patents

Years Active: 2003-2026

Loading Chart...

Areas of Expertise:

Pegylated Uricase

Synthetic Nanocarriers

Allergy Therapy

Immune Tolerance

Immunosuppressants

Pharmacodynamic Dosing

T Cell Regulation

Polysaccharide Compositions

Gene Expression Modulation

Tissue Targeting

Humoral Immune Responses

LFA-1 Binding

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12553041 - Formulations and doses of pegylated uricase (2026-02-17),

2. 11779641 - Tolerogenic synthetic nanocarriers for allergy therapy (2023-10-10),

3. 11633422 - Methods and compositions for attenuating anti-viral transfer vector immune responses (2023-04-25),

4. 10441651 - Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells (2019-10-15),

5. 10434088 - Methods related to administering immunosuppressants and therapeutic macromolecules at a reduced pharmacodynamically effective dose (2019-10-08),

6. 10420835 - Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cells (2019-09-24),

7. 10357483 - Methods comprising dosing combinations for reducing undesired humoral immune responses (2019-07-23),

8. 10335395 - Methods of administering immunosuppressants having a specified pharmacodynamic effective life and therapeutic macromolecules for the induction of immune tolerance (2019-07-02),

9. 10071114 - Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses (2018-09-11),

10. 10046064 - Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses (2018-08-14),

11. 10004802 - Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells (2018-06-26),

12. 9987354 - Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cells (2018-06-05),

13. 9387256 - Tissue targeting (2016-07-12),

14. 9358252 - Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization (2016-06-07),

15. 9351992 - Non-anticoagulant polysaccharide compositions (2016-05-31),

Title: Takashi Kei Kishimoto: Innovator in Allergy Therapy and Immunology

Introduction

Takashi Kei Kishimoto, based in Lexington, MA, USA, is an accomplished inventor with a remarkable portfolio of 25 patents. His work primarily focuses on innovative solutions within the field of allergy therapy and immunology. Kishimoto's contributions leverage advanced nanotechnology to address complex immune responses, making significant strides in the medical field.

Latest Patents

Among his latest patents is a groundbreaking work titled "Tolerogenic Synthetic Nanocarriers for Allergy Therapy." This patent discloses synthetic nanocarrier compositions and related methods that incorporate immunosuppressants and MHC Class II-restricted epitopes of allergens. The resulting compositions facilitate tolerogenic immune responses specific to the allergens, presenting a pioneering approach to treat allergic reactions. Another notable patent from his collection is "Methods and Compositions for Attenuating Anti-Viral Transfer Vector Immune Responses." This patent outlines methods and related compositions designed to enhance the administration of viral transfer vectors alongside antigen-presenting cell-targeted immunosuppressants, which could potentially transform methodologies in immunotherapy.

Career Highlights

Kishimoto has made significant impacts during his tenure at Selecta Biosciences, Inc. and Momenta Pharmaceuticals, Inc. His innovative mindset and dedication to advancing immunological treatments have positioned him as a prominent figure within the biotechnology sector.

Collaborations

Throughout his career, Kishimoto has collaborated with other esteemed professionals, including Roberto A. Maldonado and Christopher C. Fraser. These collaborations have further cemented his reputation as a thought leader in the field of immunology.

Conclusion

Takashi Kei Kishimoto's contributions to the fields of allergy therapy and immunology are noteworthy as he continues to push the boundaries of science through his inventive spirit. His accomplishments remind us of the profound impact that innovations can have on improving health and well-being.

Profile summary based on public USPTO records.